INTRA – Integrin Targeted Radioligands | EU & Saxony Co-funded R&D Project
Diese Maßnahme wird mitfinanziert durch Steuermittel auf der Grundlage des vom sächsischen Landtag beschlossenen Haushaltes.
Advancing αvβ6-integrin targeted radiopharmaceuticals
INTRA is a research and development project focused on αvβ6-integrin as a molecular target for radiopharmaceutical approaches in epithelial cancers. Building on TRIMT’s αvβ6-targeting platform and [^68Ga]Ga-Trivehexin®, the project aims to advance new approaches for PET imaging and targeted radionuclide therapy.
The project combines radiopharmaceutical design, preclinical development and clinical translation to further explore the potential of αvβ6-integrin targeted theranostics.
Project Objective:
The objective of INTRA is to expand αvβ6-integrin targeting beyond diagnostic imaging towards therapeutic applications. Research activities include the optimization of αvβ6-targeting radioligands, approaches to improve pharmacokinetic properties and reduce renal uptake, and the development of radiopharmaceuticals using therapeutic radionuclides such as Lutetium-177.
In parallel, the project explores opportunities to further improve αvβ6-targeted PET imaging.
Results:
Research performed within INTRA has contributed to advances in αvβ6-targeted radiopharmaceutical development, including:
- strategies to reduce renal uptake of radiolabeled αvβ6-targeting peptides,
- optimization of multivalent peptide-based radioligands,
- further development of αvβ6-targeted PET imaging,
- translation of an αvβ6-targeted ^68Ga/^177Lu theranostic approach into first clinical applications.
Published clinical experience supports the potential of αvβ6-integrin targeting for both molecular imaging and radioligand therapy, including applications in pancreatic ductal adenocarcinoma.
Project Facts:
- Project: INTRA – Integrin Targeted Radioligands
- Beneficiary: TRIMT GmbH
- Location: Radeberg, Saxony, Germany
- Project period: May 2023 – December 2026
- Field: Radiopharmaceutical research & development
- Focus: αvβ6-integrin targeted cancer imaging and radioligand therapy
- Funding: Co-funded by the European Union and the Free State of Saxony